Edgewise Therapeutics, Inc. (EWTX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $61.15M | +46.8% |
| 2024 | $41.67M | -51.6% |
| 2023 | $86.10M | +291.5% |
| 2022 | $21.99M | +41.3% |
| 2021 | $15.57M | -85.2% |
| 2020 | $104.92M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $61.15M | +46.8% |
| 2024 | $41.67M | -51.6% |
| 2023 | $86.10M | +291.5% |
| 2022 | $21.99M | +41.3% |
| 2021 | $15.57M | -85.2% |
| 2020 | $104.92M | — |